The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.
Phase:
PHASE3
Details
Lead Sponsor:
Nordsjaellands Hospital
Collaborators:
Steno Diabetes Center Aarhus (SDCA), Aarhus University Hospital Steno Diabetes Center Copenhagen Steno Diabetes Center Odense Zealand University Hospital